PreveCeutical Medical Inc.
PRVCF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $3 | $3 | $0 | $0 |
| Gross Profit | -$3 | -$3 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $48 | $187 | $436 | $84 |
| G&A Expenses | $0 | $987 | $224 | $55 |
| SG&A Expenses | $503 | $987 | $224 | $117 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $63 |
| Other Operating Expenses | $0 | $25 | $15 | -$48 |
| Operating Expenses | $552 | $1,199 | $675 | $153 |
| Operating Income | -$554 | -$1,199 | -$675 | -$153 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$62 | -$56 | -$89 | -$88 |
| Pre-Tax Income | -$616 | -$1,255 | -$764 | -$242 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$587 | -$1,255 | -$764 | -$242 |
| % Margin | – | – | – | – |
| EPS | -0.001 | -0.002 | -0.001 | -0 |
| % Growth | 54.5% | -57.1% | -250% | – |
| EPS Diluted | -0.001 | -0.002 | -0.001 | -0 |
| Weighted Avg Shares Out | 572,135 | 561,816 | 536,112 | 536,939 |
| Weighted Avg Shares Out Dil | 572,135 | 561,816 | 536,112 | 536,939 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $58 | $79 | $82 | $82 |
| Depreciation & Amortization | $3 | $4 | $3 | $3 |
| EBITDA | -$556 | -$1,172 | -$678 | -$157 |
| % Margin | – | – | – | – |